Increased STAT1 signaling in endocrine-resistant breast cancer

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Huang, Rui ^a   Faratian, Dana ^a   Sims, Andrew H ^a   Wilson, Danielle ^a   Thomas, Jeremy S ^b   Harrison, David J ^c   Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIGALLOCATECHIN GALLATE; ESTROGEN; PROTEIN INHIBITOR OF ACTIVATED STAT; STAT1 PROTEIN; STAT3 PROTEIN; STATTIC; TAMOXIFEN; UNCLASSIFIED DRUG; WP 1066; 3 (6 BROMO 2 PYRIDINYL) 2 CYANO N (1 PHENYLETHYL)ACRYLAMIDE; CATECHIN; PYRIDINE DERIVATIVE; SULFOXIDE; TYRPHOSTIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOINFORMATICS; BREAST CANCER; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DATA ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS FREE SURVIVAL; DRUG PROTEIN BINDING; DRUG SENSITIVITY; DRUG TARGETING; FUNCTIONAL PROTEOMICS; GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC DATABASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; INTERMETHOD COMPARISON; LYMPH NODE; LYMPH NODE METASTASIS; PREDICTIVE VALUE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT1 GENE; STAT3 GENE; TISSUE DISTRIBUTION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECTS; FEMALE; GENETICS; MCF 7 CELL LINE; METABOLISM; POLYMERASE CHAIN REACTION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CATECHIN; CELL SURVIVAL; CYCLIC S-OXIDES; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; POLYMERASE CHAIN REACTION; PYRIDINES; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TAMOXIFEN; TYRPHOSTINS;

EID: 84899658186     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094226     Document Type: Article

References (46)

1. Stark GR, Darnell JE Jr (2012) The JAK-STAT pathway at twenty. Immunity 36: 503-514.
2. Bromberg J, Darnell JE Jr (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19: 2468-2473. (Pubitemid 30339202)
3. Mohr A, Chatain N, Domoszlai T, Rinis N, Sommerauer M, et al. (2012) Dynamics and non-canonical aspects of JAK/STAT signalling. Eur J Cell Biol 91: 524-532.
4. Levy DE, Darnell JE Jr (2002) STATS: Transcriptional control and biological impact. Nature Rev Mol Cell Biol 3: 651-662. (Pubitemid 34987786)
5. Yu H, Jove R (2004) The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4: 97-105. (Pubitemid 38198738)
6. Furth PA (2013) STAT signaling in different breast cancer sub-types. Mol Cell Endocrinol 382: 612-615.
7. Clevenger CV (2004) Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165: 1449-1460. (Pubitemid 39435145)
8. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M et al. (2003). STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol 197: 157-168. (Pubitemid 37485244)
9. Bromberg JF (2002) Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142.
10. Silva CM, Shupnik MA (2007) Integration of Steroid and Growth Factor Pathways in Breast Cancer: Focus on Signal Transducers and Activators of Transcription and Their Potential Role in Resistance. Mol Endocrinol, 21: 1499-1512. (Pubitemid 47001077)
11. Regis G, Pensa S, Boselli D, Novelli F, Poli V (2008) Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. Sem Cell Devel Biol 19: 351-359, 2008.
12. Charpin C, Secq V, Giusiano S, Carpentier S, Andrac L, et al. (2009) A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 124: 2124-2134.
13. Magkou C, Giannopoulou I, Theohari I, Fytou A, Rafailidis P, et al. (2012) Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathol, 60: 1125-1132.
14. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, et al. (2002) Prognostic significance of signal transducer and activator of transcription 1 activation in breastcancer. Clin Cancer Res, 8: 3065-3074 (Pubitemid 35155015)
15. Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL (2003) Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res 9: 594-600. (Pubitemid 36182589)
16. Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, et al. (2012) Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol 14: 232-236.
17. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, et al. (2006) Activation of STAT 3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res, 12: 20-28. (Pubitemid 43166171)
18. Sheen-Chen SM, Huang CC, Tang RP, Chou FF, Eng HL (2008) Prognostic value of signal transducers and activators of transcription 3 in breast cancer. Cancer Epidemiol Biomarkers Prev. 17: 2286-2290
19. Yeh YT, Ou-Yang F, Chen IF, Yang SF, Wang YY, et al. (2006) STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 118: 2943-2947.
20. Choi J, Kim do H, Jung WH, Koo JS (2013) Differential expression of immunerelated markers in breast cancer by molecular phenotypes. Breast Cancer Res Treat, 137: 417-429.
21. Brünner N, Boulay V, Fojo A, Freter CE, Lippman ME, et al. (1993) Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications. Cancer Res 53: 283-290. (Pubitemid 23031838)
22. Brünner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, et al. (1997) MCF7/ LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res 57: 3486-3493. (Pubitemid 27355496)
23. Tedeschi E, Suzuki H, Menegazzi M (2002) Anti-inflammatory action of EGCG, the main component of green tea, through STAT-1 inhibition. Ann N Y Acad Sci 973: 435-437. (Pubitemid 36125048)
24. McMurray JS (2006) A new small-molecule Stat3 inhibitor. Chem Biol 13: 1123-1124. (Pubitemid 44750737)
25. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol. 13: 1235-1242. (Pubitemid 44750735)
26. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, et al. (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26: 2435-2444. (Pubitemid 46597261)
27. Szelag M, Sikorski K, Czerwoniec A, Szatkowska K, Wesoly J, et al. (2013) In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain crossbinding specificity. Eur J Pharmacol. 720: 38-48.
28. Camp RL, Chung GG, Rimm DL (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327. (Pubitemid 35373567)
29. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003 Feb 15;31(4):e15.
30. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 8:118-27. (Pubitemid 44906106)
31. Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res, 10:7252-9. (Pubitemid 39487712)
32. Altman DG, Lausen B, Sauerbrei W, Schumacher M (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst, 86:829-35. (Pubitemid 2100935)
33. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DS, Baker SW, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci U S A 105:18490-18495.
34. Khodarev N, Ahmad R, Rajabi H, Pitroda S, Kufe T, et al. (2010) Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 29: 920-929.
35. Englert NA, Spink BC, Spink DC (2011) Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 123:140-150.
36. Becker M, Sommer A, Krätzschmar JR, Seidel H, Pohlenz HD, et al. (2005) Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4:151-168. (Pubitemid 40268073)
37. Chisholm K, Bray BJ, Rosengren RJ (2004) Tamoxifen and epigallocatechin gallate are synergistically cytotoxic to MDA-MB-231 human breast cancer cells. Anticancer Drugs. 15: 889-97. (Pubitemid 39482930)
38. Stuart EC, Rosengren RJ (2008) The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDAMB-231 cells. Life Sci. 82: 943-948.
39. Scandlyn MJ, Stuart EC, Somers-Edgar TJ, Menzies AR, Rosengren RJ (2008) A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br J Cancer. 99:1056-63.
40. Farabegoli F, Papi A, Orlandi M (2011) (-)-Epigallocatechin-3-gallate downregulates EGFR, MMP-2, MMP-9 and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 31: 99-108.
41. Dien J, Amin HM, Chiu N (2006) Signal transducers and activators of transcription-3 upregulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol 169: 633-642. (Pubitemid 44156319)
42. Hsieh FC, Cheng G, Lin J (2005) Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun. 335: 292-299. (Pubitemid 41140220)
43. Sheen-Chen SM, Huang CC, Tang RP, Yang CH, Chou FF, et al. (2007) Signal transducer and activator of transcription 1 in breast cancer: Analysis with tissue microarray. Anticancer Res, 27: 2481-2486.
44. Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, et al. (2006) STAT 5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocrine Rel Cancer, 13: 885-893. (Pubitemid 44763264)
45. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, et al. (2004) Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol, 22: 2053-2060. (Pubitemid 41095137)
46. Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, et al. (2011) Loss of nuclear localized and tyrosine phosphorylated STAT 5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol, 29: 2448-2458.